Eli Lilly and Company (NYSE:LLY) major shareholder Lilly Endowment Inc sold 205,000 shares of the stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Friday, September 29th, Lilly Endowment Inc sold 195,000 shares of Eli Lilly and stock. The stock was sold at an average price of $85.14, for a total transaction of $16,602,300.00.
  • On Friday, September 15th, Lilly Endowment Inc sold 190,000 shares of Eli Lilly and stock. The stock was sold at an average price of $82.53, for a total transaction of $15,680,700.00.
  • On Thursday, August 31st, Lilly Endowment Inc sold 180,000 shares of Eli Lilly and stock. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00.
  • On Monday, July 31st, Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00.

Shares of Eli Lilly and Company (NYSE LLY) traded up 0.79% during midday trading on Thursday, reaching $87.65. 5,220,959 shares of the company’s stock were exchanged. The stock has a market cap of $92.47 billion, a P/E ratio of 37.93 and a beta of 0.34. Eli Lilly and Company has a one year low of $64.18 and a one year high of $89.09. The company’s 50-day moving average is $81.75 and its 200-day moving average is $82.08.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the previous year, the business earned $0.86 earnings per share. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. Equities analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

WARNING: This article was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/05/eli-lilly-and-company-lly-major-shareholder-sells-17796050-00-in-stock.html.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Eqis Capital Management Inc. increased its position in shares of Eli Lilly and by 25.4% during the third quarter. Eqis Capital Management Inc. now owns 10,387 shares of the company’s stock worth $888,000 after purchasing an additional 2,105 shares in the last quarter. Curbstone Financial Management Corp increased its position in shares of Eli Lilly and by 101.1% during the third quarter. Curbstone Financial Management Corp now owns 13,688 shares of the company’s stock worth $1,171,000 after purchasing an additional 6,883 shares in the last quarter. MPS Loria Financial Planners LLC purchased a new stake in shares of Eli Lilly and during the second quarter worth approximately $128,000. W. E. Donoghue & Co. LLC purchased a new stake in shares of Eli Lilly and during the second quarter worth approximately $16,220,000. Finally, M Holdings Securities Inc. purchased a new stake in shares of Eli Lilly and during the second quarter worth approximately $234,000. Hedge funds and other institutional investors own 75.72% of the company’s stock.

Several brokerages have recently weighed in on LLY. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $95.00 price objective (up previously from $92.00) on shares of Eli Lilly and in a research note on Thursday. Cowen and Company reiterated a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a research note on Wednesday. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 price objective on shares of Eli Lilly and in a research note on Thursday, September 28th. Morgan Stanley reiterated a “hold” rating and issued a $86.00 price objective on shares of Eli Lilly and in a research note on Friday, September 15th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $89.00 price objective on shares of Eli Lilly and in a research note on Monday, September 11th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company. Eli Lilly and presently has an average rating of “Hold” and an average price target of $88.42.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.